# ScoreItem: Testosterona Total - Mulheres Pós-Menopausa

**ID:** `c77cedd3-2800-7a73-bd66-aeb35ff300b8`
**FullName:** Testosterona Total - Mulheres Pós-Menopausa (Exames - Laboratoriais)
**Unit:** ng/dL
**Gender:** female
**Post-Menopause:** true

**Preparation Metadata:**
- Quality Grade: **EXCELLENT**
- Total Chunks: 30 de 9 artigos
- Avg Similarity: 0.709

---

## Contexto

Você é um especialista em medicina funcional integrativa e está contribuindo com o **Escore Plenya** — um escore completo de análise de saúde que avalia todos os aspectos da saúde, performance e longevidade humana. Cada ScoreItem representa um parâmetro clínico, laboratorial, genético, comportamental ou histórico que compõe esse escore.

Seu papel é gerar conteúdo clínico de alta qualidade para enriquecer cada parâmetro do escore com relevância clínica, orientação ao paciente e conduta prática.

**Regras inegociáveis:**
- Use **apenas** o conhecimento médico real consolidado e os dados presentes nos chunks científicos abaixo
- **Não alucine, não invente** dados, estudos, estatísticas ou referências que não estejam nos chunks ou no seu conhecimento médico estabelecido
- Se um dado específico não constar nos chunks e não for do seu conhecimento consolidado, **não o inclua**
- Seja preciso: prefira omitir a inventar

## Instrução

Com base nos chunks científicos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `c77cedd3-2800-7a73-bd66-aeb35ff300b8`.**

```json
{
  "score_item_id": "c77cedd3-2800-7a73-bd66-aeb35ff300b8",
  "clinical_relevance": "Texto técnico para médicos (1000-5000 chars): definição fisiológica precisa, valores de referência e interpretação, fisiopatologia resumida, dados epidemiológicos com números concretos, estratificação de risco baseada em evidências.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que é este parâmetro sem jargões, por que é importante para a saúde, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta clínica em Markdown (1000-5000 chars): investigação complementar necessária, critérios de encaminhamento a especialistas, intervenções baseadas em evidências. Use bullet points, seções e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto clínico: 1-9 pts
- Alto impacto clínico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Critérios: gravidade/mortalidade (40%), prevalência (30%), intervencionabilidade (30%)

---

### Contexto Científico

**ScoreItem:** Testosterona Total - Mulheres Pós-Menopausa (Exames - Laboratoriais)
**Unidade:** ng/dL
**Gênero:** female

**30 chunks de 9 artigos (avg similarity: 0.709)**

### Chunk 1/30
**Article:** The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review (2022)
**Journal:** International Journal of Impotence Research
**Section:** results | **Similarity:** 0.757

antoroN.Androgensandfemalesexualfunctionanddysfunction—Findingsfromthefourthinternationalconsultationofsexualmedicine.JSexMed.2016;13.48.ShifrenJL,BraunsteinGD,SimonJA,CassonPR,BusterJE,RedmondGP,etal.Transdermaltestosteronetreatmentinwomenwithimpairedsexualfunction
afteroophorectomy.NEnglJMed.2000;343:682–8.https://doi.org/10.1056/NEJM200009073431002.49.BusterJE,KingsbergSA,BuchA,RodenbergCA,WekselmanK.Testosteronepatchforlowsexualdesireinsurgicallymenopausalwomen:arandomizedtrial.Obstet
Gynecol.2005;105:944–52.https://doi.org/10.1097/01.AOG.0000158103.27672.0d50.DavisSR,MoreauM,KrollR,BouchardC,PanayN,GassM,etal.APHRODITEStudyTeam.Testosteroneforlowlibidoinpostmenopausalwomennottakingestro-
gen.NEnglJMed.2008;359:2005–17.https://doi.org/10.1056/NEJMoa0707302.51.PanayN,Al-AzzawiF,BouchardC,DavisSR,EdenJ,LodhiI,etal.TestosteronetreatmentofHSDDinnaturallymenopausalwomen:theADOREstudy.Climac-
teric.2010;13:121–31.https://doi.org/10.3109/13697131003675922.52.SimonJ,BraunsteinG,N

---

### Chunk 2/30
**Article:** The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review (2022)
**Journal:** International Journal of Impotence Research
**Section:** results | **Similarity:** 0.743

BouchardC,DavisSR,EdenJ,LodhiI,etal.TestosteronetreatmentofHSDDinnaturallymenopausalwomen:theADOREstudy.Climac-
teric.2010;13:121–31.https://doi.org/10.3109/13697131003675922.52.SimonJ,BraunsteinG,NachtigallL,UtianW,KatzM,MillerS,etal.Testosteronepatchincreasessexualactivityanddesireinsurgicallymenopausalwomenwith
hypoactivesexualdesiredisorder.JClinEndocrinolMetab.2005;90:5226–33.https://doi.org/10.1210/jc.2004-1747.53.ShifrenJL,DavisSR,MoreauM,WaldbaumA,BouchardC,DeRogatisL,etal.Testosteronepatchforthetreatmentofhypoactivesexualdesiredisorderin
naturallymenopausalwomen:resultsfromtheINTIMATENM1Study.Meno-
pause.2006;13:770–9.https://doi.org/10.1097/01.gme.0000243567.32828.99.Erratumin:Menopause.2007Jan-Feb;14(1):157.PMID:1693224054.HuangG,BasariaS,TravisonTG,HoMH,DavdaM,MazerNA,etal.Testosteronedose-responserelationshipsinhysterectomizedwomenwithorwithout
oophorectomy:effectsonsexualfunction,bodycomposition,muscleperfor-
manceandphysicalfunctioninarandomizedtrial.Menopause.2014

---

### Chunk 3/30
**Article:** The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review (2022)
**Journal:** International Journal of Impotence Research
**Section:** discussion | **Similarity:** 0.736

.1210/jcem.83.11.5280.65.DavisSR,BraunsteinGD.Efcacyandsafetyoftestosteroneinthemanagementofhypoactivesexualdesiredisorderinpostmenopausalwomen.JSexMed.
2012;9:1134–48.https://doi.org/10.1111/j.1743-6109.2011.02634.x.66.KischeH,GrossS,WallaschofskiH,VölzkeH,DörrM,NauckM,etal.Clinicalcorrelatesofsexhormonesinwomen:ThestudyofhealthinPomerania.Meta-
bolism.2016;65:1286–96.https://doi.org/10.1016/j.metabol.2016.05.011.67.MukaT,NanoJ,JaspersL,MeunC,BramerWM,HofmanA,etal.Associationsofsteroidsexhormonesandsexhormone-bindingglobulinwiththeriskoftype2
diabetesinwomen:apopulation-basedcohortstudyandmeta-analysis.Dia-betes.2017;66:577–86.https://doi.org/10.2337/db16-0473.68.KennedyRG,DaviesT,Al-AzzawiF.Sexualinterestinpostmenopausalwomenisrelatedto5alpha-reductaseactivity.HumReprod.1997;12:209–13.https://doi.org/10.1093/humrep/12.2.209.69.WiermanME,ArltW,BassonR,DavisSR,MillerKK,MuradMH,etal.Androgentherapyinwomen:areappraisal:anEndocrineSocietyclinicalpracticeguideline.

---

### Chunk 4/30
**Article:** The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review (2022)
**Journal:** International Journal of Impotence Research
**Section:** results | **Similarity:** 0.732

surementof5α-reductaseshouldbeconsideredinpatientswithoutclinicalimprovementinsymptoms
foundtohavenormaltotaltestosteroneandfreetestosterone.Inthescenariosoflowfreetestosteroneordecreased5αreductase,expertshavesupportedtotaltestosteronelevelshigherthan
physiologictestosterone[68].Oncelevelsarestable,testosteroneconcentrationsshouldbemonitoredevery4–6months[47,62].IftestosteronetherapyresultsinimprovementofHSDD,adrugholidayshouldbe
consideredafter6–12monthsoftreatmenttoseeiftreatmentisstillrequired[24].Ifthereisadeclineinsymptomsaftercessationoftestosterone,therapyshouldthenberesumedlong-termto
maintaintheimprovementinHSDD[24].Testosteronetreatmentshouldbediscontinuedifthereisnoclinicalimprovementnotedbythepatientafter6months[23,47,69].FUTUREAREASOFRESEARCHInpremenopausalwomen,thedataismixedregardingtheefcacyofTRT.Across-sectionalstudybyZhengetal.[70]of588premenopausalwomenexaminedthecorrelationofseveral
domainsofsexualhealthbasedontheProleofFemaleSexualFunction(PFSF)questionnai

---

### Chunk 5/30
**Article:** Testosterone in women—the clinical significance (2026)
**Journal:** Revista não identificada
**Section:** results | **Similarity:** 0.730

6 months. In this study, women given testosterone had 
signiﬁ cant improvements in the 6-min walk test, oxygen consumption, and insulin resistance compared with 
those given placebo, and better performance in each of 
these tests is associated with better prognosis for 
congestive cardiac failure.54 This study does not suggest that women with congestive cardiac failure should be 
given testosterone but rather supports the need for better 
understanding of the role of testosterone in the 
pathogenesis of cardiovascular disease in women.Testosterone and cognitionEvidence from basic and clinical studies suggests that sex 
steroids a ect cognitive decline and progression to dementia in women. Findings from basic studies55,56 have shown that oestradiol and testosterone are neuroprotective 
Panel: Taking sex hormone-binding globulin into accountTestosterone in women is most often considered in the context of excess concentrations and polycystic ovary syndrome.

---

### Chunk 6/30
**Article:** The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review (2022)
**Journal:** International Journal of Impotence Research
**Section:** methods | **Similarity:** 0.720

omen.ThisarticlereviewstheliteratureontherelationshipofandrogendeclineandHSDD,describesourmethodologyforevaluation,diagnosisofHSDD,andtheuseofTRTintreatingpostmenopausalwomenwithHSDD.Ourresultsconcludethattestosteroneisavitalhormoneinwomeninmaintaining
sexualhealthandfunction.TRTisaneffectivetreatmentoptionforpostmenopausalpeoplewithHSDD.ThereisstilllimiteddataontheeffectivenessinpremenopausalpeoplewithHSDD.Furtherresearchinthestrengthsandweaknessesforthelong-termeffectofTRTinwomenofallagesisneeded.IJIR:YourSexualMedicineJournal(2022)34:635–641;https://doi.org/10.1038/s41443-022-00613-0INTRODUCTIONAndrogensareimportanthormonesthatassistintheregulationandmaintenanceofthevulvovaginalcomplex,pelvicoor,bladder,andurethraaswellasvitalsexualfunctionsincluding
vaginallubrication[1–4].Contrarytopopularbelief,androgenproductionservesagreaterimportancethanjustestrogenproductioninwomen[5].Circulatingtestosteroneismeasuredinnanomolarconcentrations(ng/dl)inwomen,anorder1000
timesmorethancircul

---

### Chunk 7/30
**Article:** Testosterone in women—the clinical significance (2026)
**Journal:** Revista não identificada
**Section:** discussion | **Similarity:** 0.713

he Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the 
assessment of female sexual function. J Sex Marital Ther 2000; 
26: 191–208.17 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington, DC: American 
Psychiatric Press, 1994.18 Elraiyah T, Sonbol MB, Wang Z, et al. Clinical review: The beneﬁ ts and harms of systemic testosterone therapy in postmenopausal 
women with normal adrenal function: a systematic review and 
meta-analysis. J Clin Endocrinol Metab 2014; 99: 3543–50.19 Davis SR, Moreau M, Kroll R, et al, and the APHRODITE Study Team. Testosterone for low libido in postmenopausal women not 
taking estrogen. N Engl J Med 2008; 359: 2005–17.20 Somboonporn W, Davis S, Seif MW, Bell R. Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev 
2005; 4: CD004509.21 Baldassarre M, Perrone AM, Giannone FA, et al.

---

### Chunk 8/30
**Article:** The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review (2022)
**Journal:** International Journal of Impotence Research
**Section:** other | **Similarity:** 0.712

r-
net].SouthDartmouth(MA):MDText.com,Inc.;2000.Availablefrom:https://www.ncbi.nlm.nih.gov/books/NBK279000/14.GuayA,MunarrizR,JacobsonJ,TalakoubL,TraishA,QuirkF,etal.Serumandrogenlevelsinhealthypremenopausalwomenwithandwithoutsexualdysfunction:partA.Serumandrogenlevelsinwomenaged20–49yearswithnocomplaintsofsexualdysfunction.IntJImpotRes.2004;16:112–20.15.BurgerHG,DudleyEC,CuiJ,DennersteinL,HopperJL.Aprospectivelongitudinalstudyofserumtestosterone,dehydroepiandrosteronesulfate,andsexhormone-
bindingglobulinlevelsthroughthemenopausetransition.JClinEndocrinol
Metab.2000;85:2832–8.16.JuddHL,LucasWE,YenSSC.Effectofoophorectomyoncirculatingtestosteroneandandrostenedionelevelsinpatientswithendometrialcancer.AmJObstetGynecol.1974;118:793–8.17.DavisSR,McCloudP,StraussBJG,BurgerH.Testosteroneenhancesestradiol’seffectsonpostmenopausalbonedensityandsexuality.Maturitas.1995;21:227–36.18.DavisSR,BurgerHG.Therationaleforphysiologicaltestosteronereplacementinwomen.Bailliere’sClinEndocrin

---

### Chunk 9/30
**Article:** Association between Serum Total Testosterone Level and Bone Mineral Density in Middle-Aged Postmenopausal Women (2022)
**Journal:** International Journal of Endocrinology
**Section:** discussion | **Similarity:** 0.711

l_Estradiol_and_Total_Testosterone.pdf.[15]J.Ye,X.Zhai,J.Yang,andZ.Zhu,“Associationbetweenserumtestosteronelevelsandbodycompositionamongmenh20-59Yearsofage,”Internationaljournalofendocrinology,vol.2021,ArticleID7523996,8pages,2021.[16]P.J.Snyder,D.L.Kopperdahl,A.J.Stephens-Shieldsetal.,“E3ectoftestosteronetreatmentonvolumetricbonedensityhandstrengthinoldermenwithlowtestosterone:acontrolledclinicaltrial,”JAMAInternalMedicine,vol.177,no.4,pp.471–479,2017.[17]R.Kacker,W.Conners,J.Zade,andA.Morgentaler,“Bonemineraldensityandresponsetotreatmentinmenyoungerthan50yearswithtestosteronedeEciencyandsexualdys-functionorinfertility,”eJournalofUrology,vol.191,no.4,pp.1072–1076,2014.[18]Z.Y.Liu,Y.Yang,C.Y.Wen,andL.M.Rong,“Serumosteocalcinandtestosteroneconcentrationsinadultmaleshwithorwithoutprimaryosteoporosis:ameta-analysis,”iBioMedResearchInternational,vol.2017,ArticleID9892048,7pages,2017.[19]B.Hsu,M.J.Seibel,R.G.Cummingetal.,“ProgressivetemporalchangeinserumSHBG,butnotins

---

### Chunk 10/30
**Article:** MFI - Reposição Hormonal - AULA 03 (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.710

integrar faixas de referência e proporções hormonais (testosterona, DHT, estradiol), além de limiares práticos.**
- Laboratórios reportam faixas distintas de testosterona total: 200–800 ng/dL como inferior–superior típico; alguns usam 1200 como superior; indivíduos podem atingir “mil e tanto”, ilustrando variabilidade e limitação de olhar um único valor atual.
- Limiar prático: acima de 500–600 ng/dL, queixas por baixa testosterona são raras; em 300 ng/dL, considerar deficiência, interpretando junto com DHT e estradiol.
- Exemplos de DHT: 500–600 (alto, sugere que não é falta de testosterona) e 400 (pode coexistir com testosterona baixa); estradiol: 20–25 (proporcional em testosterona baixa) e 20 (tudo certo quando proporcional), reforçando análise de equilíbrio hormonal.

---

### Chunk 11/30
**Article:** The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review (2022)
**Journal:** International Journal of Impotence Research
**Section:** methods | **Similarity:** 0.710

https://doi.org/10.1111/j.1743-6109.2007.00672.x.40.ClaytonAH,GoldmeierD,NappiRE,WunderlichG,Lewis-D'AgostinoDJ,PykeR.Validationofthesexualinterestanddesireinventory-femaleinhypoactivesexual
desiredisorder.JSexMed.2010;7:3918–28.https://doi.org/10.1111/j.1743-6109.2010.02016.x.41.GoebelsmannU,ArceJJ,ThorneycroftIH,MishellDRJr.SerumtestosteroneconcentrationsinwomenthroughoutthemenstrualcycleandfollowingHCG
administration.AmJObstetGynecol.1974;119:445–52.https://doi.org/10.1016/0002-9378(74)90199-9.42.WangC,CatlinDH,DemersLM,StarcevicB,SwerdloffRS.Measurementoftotalserumtestosteroneinadultmen:comparisonofcurrentlaboratorymethods
versusliquidchromatography-tandemmassspectrometry.JClinEndocrinol
Metab.2004;89:534–43.43.MillerKK,RosnerW,LeeH,HierJ,SesmiloG,SchoenfeldD,etal.Measurementoffreetestosteroneinnormalwomenandwomenwithandrogendeciency:comparisonofmethods.JClinEndocrinolMetab.2004;89:525–33.44.ViswanathanCT,BansalS,BoothB,DeStefanoAJ,RoseMJ,SailstadJ,etal.Quantitativebioanal

---

### Chunk 12/30
**Article:** MFI - Reposição Hormonal - AULA 03 (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.708

, estradiol (crítico para desejo), diidrotestosterona (DHT), ovulação, atração física, sono; contraceptivos e insônia alteram fortemente.
* Exames e confiabilidade
   - Exames de testosterona para mulheres são pouco confiáveis; deve-se priorizar a clínica e considerar teste terapêutico, monitorando exames para evitar excesso. Mesmo com testosterona “alta” em laboratório, receptores hormonais podem variar.
   - Anticoncepcionais combinados elevam SHBG, reduzem testosterona livre e atrapalham resposta à reposição. Com anticoncepcional, a testosterona administrada tende a ser sequestrada pelo SHBG, reduzindo efetividade.
* Manejo prático
   - Considerar retirar pílula quando possível: pode ocorrer queda de cabelo, acne e “desbagunça” hormonal por cerca de 3 meses; com saúde e suporte (suplementação, alimentação, exercício, modulação do eixo HPA, mitocôndrias), tende a estabilizar.

---

### Chunk 13/30
**Article:** The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review (2022)
**Journal:** International Journal of Impotence Research
**Section:** results | **Similarity:** 0.707

unctionandhyperlipidemiaarecontraindicationsforTRT.Totaltestosteroneshouldbeevaluated3–6weeksafterinitiationofTRTandrepeatedwithin6weeksanytimethereisadoseadjustmentduringtitrationtophysiologiclevelsasdeterminedbythepatient’slaboratory[24,27,29].Patientsshouldbecounseledthatitwilltakeupto12weekstoseemaximalresultsbutto
expecttoseeimprovementinsymptoms6–8weeksafterinitiationoftreatmentwithsomewomenseeingresultsasearlyas4weeks[65].Qualitativeandsubjectivetreatmentresponsesshouldbemonitored,suchasanincreaseinsexualdesire,
improvementinqualityoflife,anddecreaseinpersonaldistress[59].Self-reportedvalidatedinstruments(e.g.,FSFI,FSDS)canbeadministeredasasupplementalandobjectivemeanstoassess
treatmentoutcomes[36,39].Patientsshouldalsobeassessedforsideeffectsincludingacne,hirsutism,andandrogenicalopecia.Itisrecommendedthattotaltestosteronedoesnotmarkedlyexceedtheupperlimitofthereferencerangetodecreasethe
riskofadrenergicsideeffects[24].Thesesideeffectscanalsooccurwithnormalserumlevelsofto

---

### Chunk 14/30
**Article:** The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review (2022)
**Journal:** International Journal of Impotence Research
**Section:** methods | **Similarity:** 0.707

REVIEWARTICLE
OPEN
Theclinicalmanagementoftestosteronereplacementtherapyinpostmenopausalwomenwithhypoactivesexualdesiredisorder:areviewMariaUloko1,FarahRahman2,LeahIbrahimPuri3andRachelS.Rubin4©TheAuthor(s)2022Aswomenage,thereisanoveralldecreaseinandrogenproductionduetodeclineofovarianandadrenalfunctionduringmenopause.Androgenshavebeendemonstratedtoplayanimportantroleinsexualmotivationinwomen.Asaresult,many
postmenopausalwomenexperienceFemaleSexualDysfunction(FSD)whichareagroupofdisordersthatpertaintosexualarousal,desire,orgasm,andpain.AprevalentmanifestationofFSDisHypoactiveSexualDesireDisorder(HSDD)ortheabsenceofsexualfantasies,thoughts,and/ordesirefororreceptivitytosexualactivity.ThereisgaininginterestintheuseofTestosterone
ReplacementTherapy(TRT)forthetreatmentofHSDDinpostmenopausalwomen.ThisarticlereviewstheliteratureontherelationshipofandrogendeclineandHSDD,describesourmethodologyforevaluation,diagnosisofHSDD,andtheuseofTRTintreatingpostmenopausalwomenwithHSDD.Ourresultsconclud

---

### Chunk 15/30
**Article:** MFI - Reposição Hormonal - AULA 09 (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.706

suplemento mais prescrito, mas com resultados inconsistentes para o aumento de testosterona.
     - Revisões sistemáticas são categóricas em afirmar que não funciona para elevar a testosterona.
     - No entanto, pode melhorar a libido e a disposição, especialmente em mulheres, independentemente dos níveis de testosterona.
     - O palestrante adverte que seu uso pode desregular outros hormônios, como o aumento excessivo de DHT em algumas mulheres, tornando seu efeito imprevisível.
* **Terapias Médicas e Estratégia de Tratamento**
   - **Abordagens não medicamentosas (Prioridade 1):** Dieta, exercício, perda de peso, melhora do sono, redução do estresse e reparo de varicocele (se presente) são fundamentais e devem ser sempre orientadas.
   - **Indicações Médicas (Abordagens Sequenciais):**
     - **HCG (Gonadotrofina Coriônica Humana):** É um análogo do LH que estimula diretamente os testículos a produzirem testosterona.

---

### Chunk 16/30
**Article:** MFI - Reposição Hormonal - AULA 04 (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.705

tosterona livre” calculada do soro como decisor; incluir, quando indicado, painel salivar (testosterona, DHT, estradiol; progesterona no D22–D24) juntamente com sangue total e SHBG.
- [ ] 5. Implementar triagem de fatores ambientais/ocupacionais que elevem temperatura escrotal (vestimenta apertada, longos períodos sentado, dormir de cueca, ambientes quentes) e orientar medidas corretivas.
- [ ] 6. Estabelecer protocolo para avaliação pós-ciclo de testosterona (endógena/exógena), reconhecendo períodos de LH/FSH inibidos e evitando interpretações equivocadas de queda transitória.
- [ ] 7. Preparar leitura dos estudos recomendados sobre obesidade e hipogonadismo, bariátrica e reversão hormonal, e relações entre obesidade e andropausa, para discussão na próxima aula.
- [ ] 8. Educar equipes clínicas sobre a inadequação de prescrever inibidores de PDE5 (Viagra/Cialis) sem avaliação hormonal quando há suspeita de disfunção androgênica.
- [ ] 9.

---

### Chunk 17/30
**Article:** Association between Serum Total Testosterone Level and Bone Mineral Density in Middle-Aged Postmenopausal Women (2022)
**Journal:** International Journal of Endocrinology
**Section:** discussion | **Similarity:** 0.705

ethesameasforfemaleosteo-porosis?”EuropeanJournalofEndocrinology,vol.183,no.3,pp.R75–r93,2020.[7]V.Rochira,“Late-onsethypogonadism:bonehealth,”Andrology,vol.8,no.6,pp.1539–1550,2020.[8]G.Corona,W.Vena,A.Pizzocaroetal.,“Testosteronesupplementationandboneparameters:asystematicreviewandmeta-analysisstudy,”JournalofEndocrinologicalInves-tigation,vol.45,no.5,pp.911–926,2022.[9]N.V.Mohamad,I.N.Soelaiman,andK.Y.Chin,“Aconcisereviewoftestosteroneandbonehealth,”ClinicalInterventionsinAging,vol.11,pp.1317–1324,2016.[10]D.Arpaci,F.Saglam,F.N.Cuhaci,D.Ozdemir,R.Ersoy,andB.Cakir,“Serumtestosteronedoesnota3ectbonemineraldensityinpostmenopausalwomen,”ArchEndocrinolMetab,vol.59,no.4,pp.292–296,2015.[11]F.Wu,R.Ames,J.Clearwater,M.C.Evans,G.Gamble,andhI.R.Reid,“Prospective10-yearstudyofthedeterminantsofbonedensityandbonelossinnormalpostmenopausalwomen,includingthee3ectofhormonereplacemenththerapy,”ClinicalEndocrinology,vol.56,no.6,pp.703–711,2002.[12]D.H.Lee,S.H.Kong,H.

---

### Chunk 18/30
**Article:** The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review (2022)
**Journal:** International Journal of Impotence Research
**Section:** other | **Similarity:** 0.704

motivationinwomen,includingbutnotlimitedtoexhibitingsexualinterest,initiatingsexualactivity,andrespondingtosexualstimula-tion[17–22].Asaresult,decreasedtestosteronelevelshavebeenhypothesizedtobeanimportantandreversiblecauseofHSDD.In
2019,TheGlobalConsensusPositionStatementontheUseofTestosteroneTherapyforWomen[23]endorsedtheuseofTRTinpostmenopausalwomenwithHSDD.Thisrecommendationhasbeenwidelyacceptedandendorsedbyteninternationalsocietiesasthebestevidence-basedguidancetodateonTRTinwomen.In2021,theInternationalSocietyfortheStudyofWomen’sSexualHealth(ISSWSH)thenpublishedtherstclinicalpracticeguidelinesontheuseofTRTforthetreatmentofHSDDinmenopausalwomen[24].ThepresentarticleaimstohighlighttheuseofTRTinthemanagementofthepostmenopausalwomanexperiencing
symptomsofHSDD.Thereviewbeginsbyprovidingaconcise
denitionofHSDDundertheDSM-IVandtheevaluationanddiagnosisofHSDD.ItthendescribestheclinicaluseofReceived:19July2021Revised:21August2022Accepted:31August2022Publishedonline:5October2022
1Depa

---

### Chunk 19/30
**Article:** MFI - Reposição Hormonal - AULA 04 (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.704

itos.
- Queda de cabelo acentuada.
- TPM muito intensa em mulheres.
## Objetivo:
Aula, não consulta. Achados objetivos/patológicos gerais:
- Testosterona em homens diminui com a idade; níveis <400 ng/dL são considerados baixos.
- Baixa testosterona associada a maior ocorrência de obesidade, hipertensão, hiperlipidemia, alergias e diabetes.
- Alta prevalência de hipogonadismo hipogonadotrófico (falta de comando central) em homens obesos.
- Obesidade aumenta atividade da aromatase, resistência à insulina e apneia do sono, levando a hipogonadismo hipotalâmico.
- Obesidade pode elevar a temperatura escrotal, piorar produção de testosterona e levar a oligospermia/azoospermia.
- Exames de sangue para hormônios livres (ex.: testosterona livre) são imprecisos no Brasil, pois laboratórios calculam em vez de medir diretamente; ~80% dos hormônios livres aderem às hemácias e são removidos na centrifugação.

---

### Chunk 20/30
**Article:** The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review (2022)
**Journal:** International Journal of Impotence Research
**Section:** other | **Similarity:** 0.702

yorinternationally
[42,43].Ifavailable,liquidchromatography(LC)/gaschromatography(GC)andLC-tandemmassspectrometry(MS/MS)assaysshouldbeusedinsteadtomeasuretotaltestosterone,asitprovidesamore
reliableandaccuratetest[24,42,44–46].Thereferencerangeofnormaltestosteroneinwomenisprovided.(Table2).AlthoughthereisnoabsolutetestosteronevalueassociatedwithHSDD[4,33,47],itisrecommendedtonotprescribetestosteronetomenopausalwomenwithsignsofelevatedandrogens(androgenicalopecia,hirsutism,acne,etc)ortestoster-onelevelsinthemidorhighranges[24].PatientswithlowtestosteroneinthesettingofelevatedSHBGoronantiandrogen
therapy(spironolactone,nasteride,etc.)shouldbecounseledontheriskthattheymayhavemutedbenetsfromtherapy.Initiationoftestosteronecanstillbeattemptedinpatientswithnonmodi-ablecausesofelevatedSHBG[48].EVIDENCEFORTESTOSTERONEINHSDDTestosteronehasbeenshowntobeeffectivealoneorwithusedinconjunctionwithestrogeninpostmenopausalwomen.A
Fig.1Overviewofandrogensynthesisinthepremenopausalovaryandadrenalgl

---

### Chunk 21/30
**Article:** Testosterone in women—the clinical significance (2026)
**Journal:** Revista não identificada
**Section:** results | **Similarity:** 0.702

double-blind, placebo-controlled study. 
J Clin Endocrinol Metab 2006; 91: 1683–90.80 Popat VB, Calis KA, Kalantaridou SN, et al. Bone mineral density in young women with primary ovarian insu  ciency: results of a 
three-year randomized controlled trial of physiological transdermal 
estradiol and testosterone replacement. 
J Clin Endocrinol Metab 2014; 99: 3418–26.81 Dobs AS, Nguyen T, Pace C, Roberts CP. Di erential e ects of oral estrogen versus oral estrogen-androgen replacement therapy on 
body composition in postmenopausal women. 
J Clin Endocrinol Metab 2002; 87: 1509–16.82 Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001; 2: 133–40.83 Davis SR. Cardiovascular and cancer safety of testosterone in women. Curr Opin Endocrinol Diabetes Obes 2011; 18: 198–203.84 Peters AA, Buchanan G, Ricciardelli C, et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast 
cancer.

---

### Chunk 22/30
**Article:** Testosterone in women—the clinical significance (2026)
**Journal:** Revista não identificada
**Section:** introduction | **Similarity:** 0.699

purpose has not impeded the widespread use of testosterone by women—either o -label or as compounded therapy. 
Observational studies indicate that testosterone has favourable cardiovascular e ects measured by surrogate 
outcomes; however, associations between endogenous testosterone and the risk of cardiovascular disease and total 
mortality, particularly in older women, are yet to be established. Adverse cardiovascular e ects have not been seen in 
studies of transdermal testosterone therapy in women. Clinical trials suggest that exogenous testosterone enhances 
cognitive performance and improves musculoskeletal health in postmenopausal women. Unmet needs include the 
availability of approved testosterone formulations for women and studies to elucidate the contribution of testosterone 
to cardiovascular, cognitive, and musculoskeletal health and the risk of cancer.IntroductionTestosterone is a critical but enigmatic female hormone.

---

### Chunk 23/30
**Article:** Terapia de Reposição Hormonal Feminina III (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.699

enos) e toxinas ambientais.
### 4. Reposição de Testosterona em Mulheres
*   **Indicações e Benefícios:**
    - A principal indicação é a desordem de hipoatividade sexual (baixo desejo sexual).
    - Melhora a massa óssea e muscular, o desejo sexual e diminui escores de depressão, especialmente em mulheres com deficiência severa.
    - Ajuda a prevenir a fragilidade associada ao envelhecimento.
*   **Segurança:**
    - A reposição com testosterona não oral em níveis fisiológicos não demonstrou aumentar o risco de cancro da mama, com alguns estudos sugerindo até um efeito protetor.
### 5. Recomendações de Tratamento e Abordagem Holística
*   **Terapia Ideal:**
    - A combinação de **17-beta-estradiol transdérmico** com **progesterona natural micronizada oral** é considerada a mais segura e benéfica.
*   **Dosagens e Vias:**
    - **Estradiol:** Gel (0,3-2,5 mg) ou adesivos (50-100 mcg). A dose é ajustada clinicamente.

---

### Chunk 24/30
**Article:** Psiquiatria Metabólica Funcional Integrativa AULA 19 (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.699

na ligadora de hormônios sexuais), que se liga com alta afinidade à testosterona, reduzindo sua biodisponibilidade.
   - Há menor síntese de testosterona ovariana por bloqueio de LH e possível redução de androgênese adrenal; a produção feminina já é limitada, agravada pela SHBG elevada.
* Medição e terapêutica de testosterona em mulheres
   - Teste sanguíneo de testosterona feminina é pouco fidedigno devido aos níveis muito baixos; avaliação salivar é considerada mais precisa, assim como cortisol salivar.
   - Prescrição: em mulheres sem anticoncepcionais e com sintomas (fadiga, baixa libido), podem-se testar baixas doses de creme de testosterona com avaliação de resposta; não esperar ganho de massa magra com creme.
   - Em usuárias de anticoncepcionais, recuperar testosterona livre é difícil; seriam necessárias “mega doses”, o que não vale pela captura pela SHBG.

---

### Chunk 25/30
**Article:** The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review (2022)
**Journal:** International Journal of Impotence Research
**Section:** other | **Similarity:** 0.696

[40],theFemaleSexualDistressScale[39],andtheDecreasedSexualDesireScreener[37].Acomprehensivephysicalexamshouldbeperformedincludingadetailedgenitalexam,examiningforsignsofhypogonadismlike
decreasedclitoralsize,labialresorption,vestibularerythemaorpallor,degreeofvaginalatrophy,andelevatedvaginalpH.Acompletehormonalpanelshouldbeobtainedincludingtotaltestosterone,free
testosterone,estradiol,andSHBG.Estradiol,prolactin,andthyroid-stimulatinghormonecanalsobeorderedifindicated[27].Duetothelowlevelsoftestosteronelevelsinwomencomparedtomen,
therearelimitationsinprecisionintheavailableassaysusedto
measuretestosterone.Radioimmunoassay(RIA)isthemostusedtechniquetomeasuretotaltestosteroneinwomen[41].Thisassayisoftenunreliableinwomen,asithasnotbeenstandardizedto
measuretestosteronelevelsinwomennationallyorinternationally
[42,43].Ifavailable,liquidchromatography(LC)/gaschromatography(GC)andLC-tandemmassspectrometry(MS/MS)assaysshouldbeusedinsteadtomeasuretotaltestosterone,asitprovidesamore
reliablean

---

### Chunk 26/30
**Article:** The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review (2022)
**Journal:** International Journal of Impotence Research
**Section:** results | **Similarity:** 0.694

tosteroneisunboundfromalbuminorSHBG,itcanbindtotheARasfreetestosteroneorbeconvertedtothemorepotentDHTwhichhasastrongerafnitytotheAR[9].Onceboundtothereceptor,itistranslocatedintothenucleusforgenetranscription[12].Thisresultsingeneactivationofvariouscellularactivityincludingmetabolism,cognition,andsexualfunction[13].Aswomenage,thereisanoveralldecreaseinandrogenproductionduetoage-relateddeclineofovarianandadrenalfunction,whichoccursduringmenopause[14].ThesteadydeclineoftestosteronebeginsafterearlyreproductiveyearswithasmallincreaseduringmenopauseduetothedecreaseinSHGB[15].Incomparison,womenwhoundergosurgicalmenopausehavea
markedandpermanentdecreaseintestosteroneproduction[16].Theirlevelsareupto50%lowerthanwomenwhoundergomenopausenaturally[16].Androgenshavebeendemonstratedtoplayaroleinsexualmotivationinwomen,includingbutnotlimitedtoexhibitingsexualinterest,initiatingsexualactivity,andrespondingtosexualstimula-tion[17–22].Asaresult,decreasedtestosteronelevelshavebeenhypothesizedtobeanim

---

### Chunk 27/30
**Article:** Testosterone in women—the clinical significance (2026)
**Journal:** Revista não identificada
**Section:** other | **Similarity:** 0.691

and naturally menopausal women. The 
ﬁ ndings from these studies have been comprehensively summarised in a Cochrane review20 and a clinical practice guideline from The Endocrine Society.4 The latter concluded, “Evidence supports the short-term 
e  cacy and safety of high physiological doses of [testosterone] treatment of post-menopausal women with sexual dysfunction due to hypoactive sexual desire 
disorder”.4 The guideline also recommends considering a 6-month therapeutic trial of transdermal testosterone 
for women who have been diagnosed with hypoactive 
sexual desire disorder according to DSM-IV.17 As described below, many of these studies have contributed 
to the understanding of the e ects of testosterone on other health outcomes.Testosterone and vaginal healthVulvovaginal atrophy is traditionally treated with low-
dose oestrogen given vaginally, which is highly e ective and safe.

---

### Chunk 28/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** results | **Similarity:** 0.689

sely associated with glucose concentration in the medium. J Steroid Biochem Mol Biol. 2000;75(23):15966. 8. De Menezes KJ, Peixoto C, Nardi AE, Carta MG, Machado S, Veras AB. Dehydroepiandrosterone, its sulfate and cognitive functions. Clin Pract Epidemiol Ment Health CP EMH. 2016;12:24. 9. Ma Y, Fan X, Han J, Cheng Y, Zhao J, Fang W, et al. Critical illness and sex hormones: response and impact of the hypothalamicpituitarygonadal axis. Therap Adv Endocrinol Metab. 2025;16:20420188251328190. 10. Kawakita T, Yasui T, Yoshida K, Matsui S, Iwasa T. Correlations of andros-tenediol with reproductive hormones and cortisol according to stages during the menopausal transition in Japanese women. J Steroid Biochem Mol Biol. 2021;214: 106009. 11. Colldén H, Nilsson ME, Norlén A-K, Landin A, Windahl SH, Wu J, et al. Dehydroepiandrosterone supplementation results in varying tissue-speciﬁc levels of dihydrotestosterone in male mice. Endocrinology. 2022;163(12):163. 12.

---

### Chunk 29/30
**Article:** MFI - Reposição Hormonal - AULA 04 (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.689

e as indicações de exames salivares como ferramenta diagnóstica mais precisa em cenários específicos.
## Conteúdo Remanescente
1. Estudos que demonstram a segurança da otimização hormonal.
2. Evidências para prescrição de testosterona em mulheres.
3. Proporcionalidade ideal entre marcadores hormonais.
## Conteúdo Abordado
### 1. Variação da Testosterona e Declínio ao Longo da Vida
- A testosterona varia ao longo do dia em homens.
- Em mulheres em idade fértil (sem contraceptivos hormonais), a testosterona varia conforme o dia e o ciclo menstrual, com pico próximo à ovulação, influenciando a libido.
- Em homens, os níveis de testosterona (total, livre, biodisponível) diminuem com a idade.
- O ideal é acompanhar os níveis hormonais desde cedo para estabelecer um basal ótimo individual.
- Níveis abaixo de 400 já se associam a queixas e maior risco de obesidade, hipertensão, hiperlipidemia e diabetes.

---

### Chunk 30/30
**Article:** MFI - Reposição Hormonal - AULA 03 (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.689

vida.
   - Em materiais didáticos do Dr. Merwin/Morgan Taylor, resultados foram apresentados como sem aumento de risco (“harmful zero”) e com benefícios gerais na reposição quando bem indicada.
* Prevenção vs tratamento agudo
   - A testosterona não “salva” no evento agudo (infarto), mas pode ter papel preventivo ao melhorar fatores de risco e estado geral (ex.: composição corporal, energia, bem-estar).
### 4. Avaliação clínica e questionários
* Ferramentas de triagem
   - Questionários citados: St. Louis University (ADAM), AMS, MMAS, HRS. Podem ser baixados, mas o instrutor considera desnecessários como único critério, devido à ampla inespecificidade dos sintomas.
* Sintomas e sinais de baixa testosterona
   - Homens: irritabilidade, fadiga, baixa libido, diminuição de pelos nas pernas, depressão, sarcopenia, aumento de gordura (principalmente abdominal), insônia, disfunção erétil.

---

